Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-05-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第二届监事会第二十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 29th meeting of the second Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and the approval of the allocation of reserved shares under the first employee stock ownership plan. The document includes voting results and confirms compliance with relevant laws and company articles. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement of a board/management decision related to employee stock plans, which falls under Board/Management Information (MANG). The document length is short (1362 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2021-05-14 Chinese
关于第一期员工持股计划预留份额分配的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the allocation of reserved shares under the first employee stock ownership plan. It details the progress, allocation, and verification of the reserved shares, including board and supervisory approvals and independent director opinions. The content focuses on employee stock plan share allocations and related governance, not on financial results, earnings, or regulatory filings. The document length is about 3,152 characters, which is relatively short but contains substantive information about share allocation rather than just announcing a report. This fits best under the category of Capital/Financing Update (CAP), as it relates to share allocation and employee stock ownership plan implementation, which affects the company's capital structure and financing arrangements.
2021-05-14 Chinese
第二届董事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, attendance, and the approval of an employee stock ownership plan allocation. There is no financial data or comprehensive report content, but rather a disclosure of board decisions and meeting procedures. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short (1024 characters), and it is not an announcement of a report publication or a regulatory filing. Therefore, the classification is MANG with high confidence.
2021-05-14 Chinese
关于召开2020年年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2020 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (both in-person and online), agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and voting instructions. The document does not contain the actual annual report or financial statements but rather serves as a notice and guide for shareholders to participate in the AGM. The presence of agenda items like the 2020 annual report and financial budget report indicates it is related to the AGM, but since it is a notice about the meeting and voting process rather than the report itself, it fits the category of AGM Information (AGM-R). The document length (5623 characters) and content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2021-05-13 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司首次公开发行股票并在创业板上市持续督导保荐总结报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导保荐总结报告书" which translates to "Continuous Supervision Sponsorship Summary Report" related to the initial public offering (IPO) and listing of Shenzhen BGI Genomics Co., Ltd. on the Shenzhen Stock Exchange Growth Enterprise Market. It details the sponsor's ongoing supervision work, commitments by shareholders and management regarding share lock-up periods, compliance with regulatory requirements, and the use of raised funds. The document includes no financial statements or quarterly/yearly financial data but focuses on regulatory compliance, sponsor duties, and shareholder commitments post-IPO. It is a summary report by the sponsor on continuous supervision rather than a full annual report, audit report, or earnings release. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory compliance and supervision report that does not fit other specific categories like Annual Report or Interim Report.
2021-05-11 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2020年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is a detailed tracking report from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd. for the year 2020. It includes extensive information about the sponsor's work overview, company governance, compliance with regulations, shareholder commitments, share lock-up and repurchase commitments, dividend policies, and other corporate governance and compliance matters. The content is focused on monitoring and reporting on the company's adherence to regulatory and sponsor obligations rather than presenting financial statements or earnings data. It is not an annual report, earnings release, or audit report. It is also not a simple announcement or a proxy statement. The document is a comprehensive report related to the sponsor's tracking and oversight activities, which aligns with the category of Regulatory Filings (RNS) as it does not fit neatly into other specific categories and serves as a regulatory compliance and monitoring report.
2021-05-11 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.